Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimer's Type Dementia.

Pretorius L, Kell DB, Pretorius E.

Front Neurosci. 2018 Nov 16;12:851. doi: 10.3389/fnins.2018.00851. eCollection 2018. Review.

2.

Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson's Disease, Alzheimer's Disease and Type 2 Diabetes Mellitus.

de Waal GM, Engelbrecht L, Davis T, de Villiers WJS, Kell DB, Pretorius E.

Sci Rep. 2018 Nov 14;8(1):16798. doi: 10.1038/s41598-018-35009-y.

3.

An automated Design-Build-Test-Learn pipeline for enhanced microbial production of fine chemicals.

Carbonell P, Jervis AJ, Robinson CJ, Yan C, Dunstan M, Swainston N, Vinaixa M, Hollywood KA, Currin A, Rattray NJW, Taylor S, Spiess R, Sung R, Williams AR, Fellows D, Stanford NJ, Mulherin P, Le Feuvre R, Barran P, Goodacre R, Turner NJ, Goble C, Chen GG, Kell DB, Micklefield J, Breitling R, Takano E, Faulon JL, Scrutton NS.

Commun Biol. 2018 Jun 8;1:66. doi: 10.1038/s42003-018-0076-9. eCollection 2018.

4.

Ultra-high throughput functional enrichment of large monoamine oxidase (MAO-N) libraries by fluorescence activated cell sorting.

Sadler JC, Currin A, Kell DB.

Analyst. 2018 Sep 24;143(19):4747-4755. doi: 10.1039/c8an00851e.

5.

The Potential of LPS-Binding Protein to Reverse Amyloid Formation in Plasma Fibrin of Individuals With Alzheimer-Type Dementia.

Pretorius E, Bester J, Page MJ, Kell DB.

Front Aging Neurosci. 2018 Aug 22;10:257. doi: 10.3389/fnagi.2018.00257. eCollection 2018.

6.

Fast and Flexible Synthesis of Combinatorial Libraries for Directed Evolution.

Sadler JC, Green L, Swainston N, Kell DB, Currin A.

Methods Enzymol. 2018;608:59-79. doi: 10.1016/bs.mie.2018.04.006. Epub 2018 May 24.

PMID:
30173773
7.

PartsGenie: an integrated tool for optimizing and sharing synthetic biology parts.

Swainston N, Dunstan M, Jervis AJ, Robinson CJ, Carbonell P, Williams AR, Faulon JL, Scrutton NS, Kell DB.

Bioinformatics. 2018 Jul 1;34(13):2327-2329. doi: 10.1093/bioinformatics/bty105.

PMID:
29949952
8.

Energetic evolution of cellular Transportomes.

Darbani B, Kell DB, Borodina I.

BMC Genomics. 2018 May 30;19(1):418. doi: 10.1186/s12864-018-4816-5.

9.

Engineering the "Missing Link" in Biosynthetic (-)-Menthol Production: Bacterial Isopulegone Isomerase.

Currin A, Dunstan MS, Johannissen LO, Hollywood KA, Vinaixa M, Jervis AJ, Swainston N, Rattray NJW, Gardiner JM, Kell DB, Takano E, Toogood HS, Scrutton NS.

ACS Catal. 2018 Mar 2;8(3):2012-2020. doi: 10.1021/acscatal.7b04115. Epub 2018 Jan 24.

10.

No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases.

Kell DB, Pretorius E.

Biol Rev Camb Philos Soc. 2018 Aug;93(3):1518-1557. doi: 10.1111/brv.12407. Epub 2018 Mar 25.

11.

Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.

Pretorius E, Page MJ, Mbotwe S, Kell DB.

PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018.

12.

Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains.

Pretorius E, Page MJ, Hendricks L, Nkosi NB, Benson SR, Kell DB.

J R Soc Interface. 2018 Feb;15(139). pii: 20170941. doi: 10.1098/rsif.2017.0941.

13.

GeneGini: Assessment via the Gini Coefficient of Reference "Housekeeping" Genes and Diverse Human Transporter Expression Profiles.

O'Hagan S, Wright Muelas M, Day PJ, Lundberg E, Kell DB.

Cell Syst. 2018 Feb 28;6(2):230-244.e1. doi: 10.1016/j.cels.2018.01.003. Epub 2018 Feb 7.

14.

Selenzyme: enzyme selection tool for pathway design.

Carbonell P, Wong J, Swainston N, Takano E, Turner NJ, Scrutton NS, Kell DB, Breitling R, Faulon JL.

Bioinformatics. 2018 Jun 15;34(12):2153-2154. doi: 10.1093/bioinformatics/bty065.

PMID:
29425325
15.

Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Kenny LC, Kell DB.

Front Med (Lausanne). 2018 Jan 4;4:239. doi: 10.3389/fmed.2017.00239. eCollection 2017.

16.

The potential therapeutic effects of ergothioneine in pre-eclampsia.

Kerley RN, McCarthy C, Kell DB, Kenny LC.

Free Radic Biol Med. 2018 Mar;117:145-157. doi: 10.1016/j.freeradbiomed.2017.12.030. Epub 2017 Dec 25. Review.

17.

Analysing and Navigating Natural Products Space for Generating Small, Diverse, But Representative Chemical Libraries.

O'Hagan S, Kell DB.

Biotechnol J. 2018 Jan;13(1). doi: 10.1002/biot.201700503. Epub 2017 Dec 6.

PMID:
29168302
18.

Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains.

Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB.

Cardiovasc Diabetol. 2017 Nov 2;16(1):141. doi: 10.1186/s12933-017-0624-5.

20.
21.

Stability in metabolic phenotypes and inferred metagenome profiles before the onset of colitis-induced inflammation.

Glymenaki M, Barnes A, Hagan SO, Warhurst G, McBain AJ, Wilson ID, Kell DB, Else KJ, Cruickshank SM.

Sci Rep. 2017 Aug 18;7(1):8836. doi: 10.1038/s41598-017-08732-1.

22.
23.

biochem4j: Integrated and extensible biochemical knowledge through graph databases.

Swainston N, Batista-Navarro R, Carbonell P, Dobson PD, Dunstan M, Jervis AJ, Vinaixa M, Williams AR, Ananiadou S, Faulon JL, Mendes P, Kell DB, Scrutton NS, Breitling R.

PLoS One. 2017 Jul 14;12(7):e0179130. doi: 10.1371/journal.pone.0179130. eCollection 2017.

24.

Mass spectrometry imaging shows major derangements in neurogranin and in purine metabolism in the triple-knockout 3×Tg Alzheimer mouse model.

Esteve C, Jones EA, Kell DB, Boutin H, McDonnell LA.

Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):747-754. doi: 10.1016/j.bbapap.2017.04.002. Epub 2017 Apr 11.

PMID:
28411106
25.
26.

Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures.

O'Hagan S, Kell DB.

J Cheminform. 2017 Mar 9;9:18. doi: 10.1186/s13321-017-0198-y. eCollection 2017.

27.

Computing exponentially faster: implementing a non-deterministic universal Turing machine using DNA.

Currin A, Korovin K, Ababi M, Roper K, Kell DB, Day PJ, King RD.

J R Soc Interface. 2017 Mar;14(128). pii: 20160990. doi: 10.1098/rsif.2016.0990.

29.

A Dormant Microbial Component in the Development of Preeclampsia.

Kell DB, Kenny LC.

Front Med (Lausanne). 2016 Nov 29;3:60. eCollection 2016. Review.

30.

Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.

Pretorius E, Akeredolu OO, Soma P, Kell DB.

Exp Biol Med (Maywood). 2017 Feb;242(4):355-373. doi: 10.1177/1535370216681549. Epub 2016 Nov 26. Review.

31.

The metabolome 18 years on: a concept comes of age.

Kell DB, Oliver SG.

Metabolomics. 2016;12(9):148. Epub 2016 Sep 2. Review.

32.

SpeedyGenes: Exploiting an Improved Gene Synthesis Method for the Efficient Production of Synthetic Protein Libraries for Directed Evolution.

Currin A, Swainston N, Day PJ, Kell DB.

Methods Mol Biol. 2017;1472:63-78. doi: 10.1007/978-1-4939-6343-0_5.

PMID:
27671932
33.

Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide.

Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB.

J R Soc Interface. 2016 Sep;13(122). pii: 20160539. doi: 10.1098/rsif.2016.0539.

34.

MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites.

O'Hagan S, Kell DB.

Front Pharmacol. 2016 Aug 22;7:266. doi: 10.3389/fphar.2016.00266. eCollection 2016.

35.

Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting.

Kell DB, Pretorius E.

Prog Biophys Mol Biol. 2017 Jan;123:16-41. doi: 10.1016/j.pbiomolbio.2016.08.006. Epub 2016 Aug 21. Review.

36.

SYNBIOCHEM Synthetic Biology Research Centre, Manchester - A UK foundry for fine and speciality chemicals production.

Ra LF, P C, A C, M D, D F, Aj J, Njw R, Cj R, N S, M V, A W, C Y, P B, R B, Gg C, Jl F, C G, R G, Db K, J M, Ns S, P S, E T, Nj T.

Synth Syst Biotechnol. 2016 Aug 25;1(4):271-275. doi: 10.1016/j.synbio.2016.07.001. eCollection 2016 Dec.

37.

Recon 2.2: from reconstruction to model of human metabolism.

Swainston N, Smallbone K, Hefzi H, Dobson PD, Brewer J, Hanscho M, Zielinski DC, Ang KS, Gardiner NJ, Gutierrez JM, Kyriakopoulos S, Lakshmanan M, Li S, Liu JK, Martínez VS, Orellana CA, Quek LE, Thomas A, Zanghellini J, Borth N, Lee DY, Nielsen LK, Kell DB, Lewis NE, Mendes P.

Metabolomics. 2016;12:109. Epub 2016 Jun 7.

38.

A Bacterial Component to Alzheimer's-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease.

Pretorius E, Bester J, Kell DB.

J Alzheimers Dis. 2016 Jun 18;53(4):1237-56. doi: 10.3233/JAD-160318. Review.

39.

SYNBIOCHEM-a SynBio foundry for the biosynthesis and sustainable production of fine and speciality chemicals.

Carbonell P, Currin A, Dunstan M, Fellows D, Jervis A, Rattray NJ, Robinson CJ, Swainston N, Vinaixa M, Williams A, Yan C, Barran P, Breitling R, Chen GG, Faulon JL, Goble C, Goodacre R, Kell DB, Feuvre RL, Micklefield J, Scrutton NS, Shapira P, Takano E, Turner NJ.

Biochem Soc Trans. 2016 Jun 15;44(3):675-7. doi: 10.1042/BST20160009.

40.

Microbes and Alzheimer's Disease.

Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WS, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA.

J Alzheimers Dis. 2016;51(4):979-84. doi: 10.3233/JAD-160152. Review. No abstract available.

41.

Response to 'The Need for Speed', by Matsson et al.

Mendes P, Oliver SG, Kell DB.

Trends Pharmacol Sci. 2016 Apr;37(4):245-246. doi: 10.1016/j.tips.2016.02.004. Epub 2016 Feb 26. No abstract available.

42.

Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness.

Kell DB.

Nat Rev Drug Discov. 2016 Feb;15(2):143. doi: 10.1038/nrd.2015.44. No abstract available.

PMID:
26837595
43.
44.

Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly.

Mendes P, Oliver SG, Kell DB.

Trends Pharmacol Sci. 2015 Nov;36(11):710-723. doi: 10.1016/j.tips.2015.07.006. Epub 2015 Nov 1. Review.

45.
47.

Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites.

O'Hagan S, Kell DB.

Front Pharmacol. 2015 May 13;6:105. doi: 10.3389/fphar.2015.00105. eCollection 2015.

48.

The dormant blood microbiome in chronic, inflammatory diseases.

Potgieter M, Bester J, Kell DB, Pretorius E.

FEMS Microbiol Rev. 2015 Jul;39(4):567-91. doi: 10.1093/femsre/fuv013. Epub 2015 May 3. Review.

49.

Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.

Pretorius E, Bester J, Vermeulen N, Alummoottil S, Soma P, Buys AV, Kell DB.

Cardiovasc Diabetol. 2015 Mar 8;14:30. doi: 10.1186/s12933-015-0192-5.

50.

A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.

O Hagan S, Swainston N, Handl J, Kell DB.

Metabolomics. 2015;11(2):323-339. Epub 2014 Sep 19.

Supplemental Content

Loading ...
Support Center